NASDAQ:BLCM - Bellicum Pharmaceuticals Stock Price, Forecast & News

Bellicum Pharmaceuticals' stock was trading at $7.29 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BLCM shares have decreased by 41.2% and is now trading at $4.29. View which stocks have been mosted impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bellicum Pharmaceuticals.

Bellicum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Bellicum Pharmaceuticals.

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) posted its quarterly earnings results on Thursday, March, 12th. The biopharmaceutical company reported ($5.82) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($4.00) by $1.82. The biopharmaceutical company had revenue of $5.13 million for the quarter, compared to analyst estimates of $0.30 million. Bellicum Pharmaceuticals had a negative return on equity of 664.19% and a negative net margin of 1,574.65%. View Bellicum Pharmaceuticals' earnings history.

Bellicum Pharmaceuticals's stock reverse split on the morning of Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of Bellicum Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

1 equities research analysts have issued 12-month price targets for Bellicum Pharmaceuticals' shares. Their forecasts range from $17.00 to $18.00. On average, they expect Bellicum Pharmaceuticals' stock price to reach $17.50 in the next year. This suggests a possible upside of 307.9% from the stock's current price. View analysts' price targets for Bellicum Pharmaceuticals.

News headlines about BLCM stock have been trending very negative on Thursday, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bellicum Pharmaceuticals earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutBellicum Pharmaceuticals.

Bellicum Pharmaceuticals saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 599,400 shares, an increase of 27.2% from the February 13th total of 471,100 shares. Based on an average daily volume of 160,400 shares, the days-to-cover ratio is presently 3.7 days. Approximately 12.1% of the shares of the company are short sold. View Bellicum Pharmaceuticals' Current Options Chain.

Some companies that are related to Bellicum Pharmaceuticals include PhaseBio Pharmaceuticals (PHAS), Chimerix (CMRX), AcelRx Pharmaceuticals (ACRX), Aravive (ARAV), Checkpoint Therapeutics (CKPT), ESSA Pharma (EPIX), Adamas Pharmaceuticals (ADMS), IDEAYA Biosciences (IDYA), Zynerba Pharmaceuticals (ZYNE), TapImmune (MRKR), SUMMIT THERAPEU/S (SMMT), Monopar Therapeutics (MNPR), SCYNEXIS (SCYX), Aquestive Therapeutics (AQST) and Eton Pharmaceuticals (ETON).

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), Cyberark Software (CYBR), TransEnterix (TRXC), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX) and ACADIA Pharmaceuticals (ACAD).

(BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BLCM stock can currently be purchased for approximately $4.29.

Bellicum Pharmaceuticals has a market capitalization of $21.66 million and generates $7.14 million in revenue each year. The biopharmaceutical company earns $-112,480,000.00 in net income (profit) each year or ($19.91) on an earnings per share basis. Bellicum Pharmaceuticals employs 173 workers across the globe. View additional information about Bellicum Pharmaceuticals.

The official website for Bellicum Pharmaceuticals is http://www.bellicum.com/.

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at 832-384-1100 or via email at [email protected]